Flat-rate pricing — one price at every dose — gets promoted as a clear advantage. Sometimes it is, sometimes it is not. It depends on your dose path and how long you stay on treatment.
When flat-rate wins
If you expect to titrate to a higher maintenance dose (10–15mg) and continue for many months, a flat rate protects you from dose-based increases and lets you predict your monthly cost from day one. For long-term, higher-dose patients, that predictability often totals less than a low entry price that climbs.
When it does not
If you are trying tirzepatide for a month or two, or staying at a low dose, a flat rate set around higher-dose costs may be higher than a provider with a genuinely low starter price. Then the flat structure charges you for predictability you will not use.
The honest question is not "is flat-rate better?" but "will I titrate up and stay on?" If yes, compare flat-rate seriously. If no, a lower entry price may serve you better. Either way, verify the actual numbers.
If predictable, dose-independent pricing is what you are after, NexLife publishes a flat rate across the full 2.5–15mg range. It is not always the lowest entry price — a short, low-dose trial may cost less elsewhere.
See NexLife flat-rate plans →Commercial/provider link. Verify current pricing on NexLife's site.